Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TITAN PHARMACEUTICAL (TTP) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (125)	7/20/2000 7:31:31 AM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 362

PFE Zeldox (Ziprasidone) continue to have problems with QTc. This time panel vote was more favorable, but with black-box warning I doubt that drug will be approved as first line therapy. <<To minimize dangers, Zeldox should carry a warning about possible effects on the heart, panel members said. Patients taking other drugs that might cause similar heart-related effects should not take Zeldox, some panelists added.>> Good news for Ilo, market is open for new better and safer drug. Miljenko